我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

骨髓干细胞移植治疗心肌梗死的临床疗效(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第5期
页码:
593-595
栏目:
临床研究
出版日期:
2008-10-20

文章信息/Info

Title:
Clinical effect of bone marrow stem cell therapy in patients with myocardial infarction treated by PCI
作者:
马会利1; 葛均波2; 钱菊英2; 孙爱军2; 牛玉宏2; 李延林2; 邹云增2; 王克强2
1．解放军第二炮兵总医院心内科，北京 100088；2．复旦大学附属中山医院心内科，上海 200032
Author(s):
A Huili1;  GE Junbo2;  QIAN Juying2;  SUN Aijun2;  NIU Yuhong2;  LI Yanlin2;  ZOU Yunzeng2;  WANG Keqiang2
1.Department of Cardiology, General Hospita, Second Artillery, PLA, Beijing 100088, China; 2.Department of Cardiology, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China
关键词:
心肌梗死; 冠状动脉介入治疗; 骨髓干细胞
Keywords:
myocardial infarction;  percutaneous coronary intervention;  bone marrow stem cell
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 了解心肌梗死(MI)患者行冠状动脉内支架置入术（percutaneous coronary intervention，PCI）后进行骨髓干细胞移植治疗的临床疗效。方法 研究对象为2003年5月～2005年12月住院的MI患者246例，其中PCI后进行骨髓干细胞移植治疗者48(男44，女4)例，年龄29~74(58±9)岁。随机选择年龄相匹配，PCI后未经骨髓干细胞移植治疗的MI者198(男178，女20)例，年龄25~70(58±9)岁。采用Judkins方法经股动脉行冠状动脉造影和左室造影。全部病例均经心脏超声检查及随访,其中96例经冠状动脉造影随访（随访率39%），随访时间1～30（96±6）个月。造影证实原支架内血管直径狭窄≥50%，定为支架内再狭窄。48例PCI后进行骨髓干细胞移植治疗者在冠状动脉造影术前2 h，局麻下选择髂后上棘穿刺抽取骨髓液40~80 ml，分离骨髓单个核细胞备用。所有患者入院后详细记录病史，体格检查，于次日晨空腹取肘静脉血检查血脂（标准酶法）、血浆纤维蛋白原（凝血酶法）水平和肝、肾功能等。结果PCI后进行骨髓干细胞移植治疗组与单纯PCI治疗组相比：年龄、性别、吸烟、高血压病、糖尿病、血脂和纤维蛋白原水平，以及冠脉血管病变支数均无显著差异；PCI后进行骨髓干细胞移植治疗组支架再狭窄发生率低（P<0.01）；两组治疗前后射血分数值改善情况均有显著统计学差异（P<0.01）。结论 PCI后进行骨髓干细胞移植治疗MI可以降低支架再狭窄率，改善心功能。
Abstract:
AIM To observe the therapeutic effects of bone marrow stem cell transplantation for patients undergoing percutaneous coronary intervention (PCI) after myocardial infarction. METHODS Enrolled in the study were 246 patients with PCI after myocardial infarction in our hospital from May, 2003 to Des, 2005. The patients were divided into two groups: 48 patients ［44 men and 4 women, mean age (58±9) years］ with bone marrow stem cell transplantation after PCI and 198 patients ［178 men and 20 women, mean age (58±9) years］ with no transplantation. Judkins was used for coronary arteriongraphy and left ventriculography. During the followup from 1 to 30 months (mean time 9.6±6 month), all the patients underwent ultracardiography and 96 of them had coronary arteriongraphy. Instent restenosis was defined by angiography. Bone marrow was reserved 2 hours before PCI for patients treated with transplatation. All the patients had their medical history recorded and physical examinations and their fast levels of fat, plasma fibrinogen, hepatic and renal function were detected from ular venous blood. SPSS11.0 software was used in all statistical analyses. RESULTS No significant differences were observed between the two group in mean age, distribution of gender, smoking, hypertension and diabetes, levels of blood fat and fibrinogen, and the number of diseased coronary arteries. However, compared with the group without transplantation, the group with transplantation had lower instent restenosis rate（P<001）and better improvement of LVEF（P<0.01）. CONCLUSION Bone marrow stem cell transplantation reduces the restenosis rate and improves the cardiac functions in patients undergoing percutaneous coronary intervention after myocardial infarction.

参考文献/References

［1］ Toma C, Pittenger MF, Cahill KS, et al. Human mensenchymal stem cells differentiate to cardiomyocyte phenotype in the adult murine heart［J］. Circulation, 2002, 105(1):93-98.

［2］ Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium［J］. Nature, 2001, 410(6829):701-705.

［3］ Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation［J］. Lancet, 2003, 361(9351):47-49.

［4］ Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications［J］. Circulation, 1990, 81(4):1161-1172.

［5］ Kawamoto A, Gwon HC, Iwaguro H, et al. Theraputic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia［J］. Circulation, 2001, 103(5):634-637.

［6］ Strauer BE, Brehm M, Zeus T, et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans［J］. Circulation, 2002, 106(15):1913-1918.

［7］ Fuchs S, Baffour R, Zhou YF, et al. Transendocardial deliveary of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia［J］. J Am Coll Cardial, 2001, 37(6):1726-1732.

［8］ Perin EC, Dohmann HF, Borojevic R, et al.Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure［J］. Circulation, 2003, 107(18):2294-2302.

［9］ Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction(TOPCAREAMI)［J］. Circulation, 2002, 106(24):3009-3017.

备注/Memo

备注/Memo:
收稿日期：2007-03-06.作者简介：马会利，主任医师，教授Email:mhlllz@sina.com.cn
更新日期/Last Update: